Biotech entity
gene-therapy is the sole category represented across all 1 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Amylyx Pharmaceuticals, all published on August 5, 2026.
Last mentioned: Aug 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 1 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Amylyx Pharmaceuticals, all published on August 5, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amylyx Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Four-Year Follow-Up Data from AMT-130 Pivotal Study
Durability of gene therapy effect expected to be reported, a key factor for regulatory decisions.
Regulatory Submissions for AMT-130 in Huntington's Disease (Planned)
uniQure aims to file for U.S. and U.K. approval in Q3 2026, targeting accelerated pathways.
AMT-260 Preliminary Data and AMT-191 Further Analyses
Six-month follow-up from the Phase I/IIa AMT-260 trial in epilepsy and new Fabry data presented.
Updated AMT-191 Phase I/II Data in Fabry Disease
Interim data demonstrate sustained enzyme activity and safety in Fabry disease patients.
Positive Topline Data for AMT-130 in Huntington's Disease
uniQure reports positive pivotal Phase I/II data, showing statistically significant improvements in disease markers.
uniQure's AMT-130 for Huntington's disease is on track for U.S. and U.K. regulatory filings in Q3 2026, following positive pivotal data. Pipeline updates for AMT-191 and AMT-260 in Fabry disease and epilepsy show a broadening gene therapy platform.
Source: rttnews.com · finanzen.ch
Amylyx Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
